JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead

While US earnings grew in 2024, revenues in China were hurt by ongoing investigations in the country.

Jan 16, 2025 - 06:00

JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead

While US earnings grew in 2024, revenues in China were hurt by ongoing investigations in the country.

Read the original article

Tags:

Previous Article

Regenxbio and Nippon Shinyaku forge $810m gene therapy deal

Insmed’s gene therapy poised to challenge DMD landscape after IND clearance

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

These are the need-to-know biotech stories from this weekend

These are the need-to-know biotech stories from this we...

Nov 13, 2023

Eisbach Bio positions HRD-targeting therapy to supplant PARP inhibitors

Eisbach Bio positions HRD-targeting therapy to supplant...

Dec 27, 2024

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Bristol Myers Squibb acquires Karuna Therapeutics for $...

Mar 20, 2024